肾移植受者的骨与矿物质疾病
肾移植后矿物质和骨代谢异常与骨折风险升高及由此导致的病残率和死亡率增加相关,钙磷紊乱、维生素D缺乏和甲状旁腺功能亢进也常见。过去几十年因免疫抑制方案变化(主要是糖皮质激素最小化或避免)骨病流行病学已发生演变。肾移植受者骨病的评估依赖于危险因素识别和骨密度评估,多种药物已用于移植后矿物质和骨代谢异常的治疗试验。
要点
- 肾移植后矿物质和骨代谢异常与骨折风险及病残率、死亡率升高相关。
- 钙磷紊乱、维生素D缺乏和甲状旁腺功能亢进在肾移植受者中常见。
- 骨病评估依赖危险因素识别和骨密度评估,多种药物已用于治疗试验。
核心结论
- 肾移植后矿物质和骨代谢异常与骨折风险升高及由此导致的病残率和死亡率增加相关。
主要发现
- 钙磷紊乱、维生素D缺乏和甲状旁腺功能亢进在肾移植受者中常见。
- 过去几十年因免疫抑制方案变化(主要是糖皮质激素最小化或避免),骨病流行病学已发生演变。
关键数值与推荐
- 肾移植受者骨病的评估依赖于危险因素识别和骨密度评估。
- 多种药物已用于移植后矿物质和骨代谢异常的治疗试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
After kidney transplantation, mineral and bone disorders are associated with higher risk of fractures and consequent morbidity and mortality. Disorders of calcium and phosphorus, vitamin D deficiency, and hyperparathyroidism are also common. The epidemiology of bone disease has evolved over the past several decades due to changes in immunosuppressive regimens, mainly glucocorticoid minimization or avoidance. The assessment of bone disease in kidney transplant recipients relies on risk factor recognition and bone mineral density assessment. Several drugs have been trialed for the treatment of post-transplant mineral and bone disorders. This review will focus on the epidemiology, effect, and treatment of metabolic and skeletal derangements in the transplant recipient.
引用
- Khairallah P, Nickolas TL. Bone and Mineral Disease in Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2021. PMID: 34127484. doi:10.2215/CJN.03410321
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。